Khaled Ziada, MD
Interventional Cardiology · Cleveland, OHNPI 1073520128
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 79.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $18,704 and has fallen 58.8% since, to $7,713 in 2025.
Across 132 payments — averaging $403.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$42K
- Genentech, Inc.$5K
- Edwards Lifesciences$3K
- Medtronic$3K
- Philips North America LLC$119
- Cathworks, Inc.$76
- plus $257 from 6 others
Across 80 payments — averaging $4673.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$154K
- Genetesis, Inc.$101K
- Abbott$56K
- Philips North America LLC$24K
- M.a. Med Alliance S.A.$23K
- Surmodics, Inc.$11K
- plus $5K from 1 others
What the payments were for
- Consulting fees$18,90035%
- Speaking & faculty fees$12,15023%
- Travel & lodging$18,55935%
- Food & beverage$3,7057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 87 | $42,497 |
| Genentech, Inc. | 7 | $4,605 |
| Edwards Lifesciences | 1 | $3,250 |
| Medtronic | 27 | $2,510 |
| Philips North America LLC | 1 | $119 |
| Cathworks, Inc. | 1 | $76 |
| Recor Medical Inc | 3 | $71 |
| Neovasc Medical Inc | 1 | $70 |
| Angiodynamics, Inc. | 1 | $45 |
| AstraZeneca | 1 | $32 |
| Acist Medical Systems, Inc. | 1 | $23 |
| Abiomed | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COROFLOW$14,597
- DRAGONFLY OPSTAR$6,775
- XIENCE SIERRA$5,500
- COROFLOW UPGRADE KIT$5,000
- TNKase$4,532
- FIELDER$2,974
- HI-TORQUE BALANCE$2,500
- SUPERA$1,726
- PROWATER$1,726
- ABSOLUTE PRO$1,726
- RESOLUTE ONYX$1,615
- PRESSUREWIRE$695
- NAVITOR$161
- ONYX FRONTIER$138
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$137
- (9520) IGT Devices Undivided$119
How this compares
$53,314 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 66 | $61,782 |
| EliquisApixaban | 58 | $54,105 |
| EntrestoSacubitril/Valsartan | 57 | $52,759 |
| JardianceEmpagliflozin | 46 | $43,825 |
| Repatha SureclickEvolocumab | 63 | $43,526 |
| XareltoRivaroxaban | 22 | $23,583 |
| Ranolazine ErRanolazine | 110 | $10,970 |
| Nebivolol Hcl | 109 | $6,003 |
| Valsartan | 107 | $2,478 |
| Metoprolol Succinate | 127 | $2,156 |
| Nitroglycerin PatchNitroglycerin | 25 | $1,839 |
| ClopidogrelClopidogrel Bisulfate | 166 | $1,816 |
| Rosuvastatin Calcium | 122 | $1,643 |
| Atorvastatin Calcium | 115 | $1,131 |
| Nitroglycerin | 54 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $32 | $61,78266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cleveland
- Grant ReedCleveland$235K
- Rishi PuriCleveland$185K
- Rayji TsutsuiCleveland$100K
- Paul PoommipanitCleveland$97K
- Jun LiCleveland$85K
- Michael ChenierCleveland$76K
- Laura YoungCleveland$51K
- Bernardo CorteseCleveland$45K
- Jason WenCleveland$37K
- Khanjan ShahCleveland$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.